Table 1 Demographics and clinical characteristics.

Data are shown as number and percentage, n (%). Age is reported in median years (minimum to maximum). Days since onset of symptoms are reported as median (minimum to maximum). Not all data were collected for HDs and recovered individuals. ARDS, acute respiratory distress syndrome; HFNC-NIV, high flow nasal cannula–noninvasive; ECMO, extracorporeal membrane oxygenation.

CharacteristicHDRecoveredModerateSevere*
n127728
Age36 (24–61)30 (20–49)59 (29–64)68 (38–81)
Male6 (46.1)5 (71.4)2 (28.6)19 (67.9)
Race
Black or African American5 (71.4)16 (57.1)
Asian or Asian American02 (7.1)
White or Caucasian2 (14.3)11 (39.2)
Past smoking history2 (14.3)13 (46.4)
Comorbidity
Obesity3 (42.9)8 (28.6)
Hypertension5 (71.4)21 (75)
Diabetes1 (14.3)7 (25)
Thromboembolic
complications
1 (14.3)7 (25)
Coronary artery disease/
myocardial infarction
03 (10.7)
Underlying lung disease†4 (57.1)7 (25)
Renal insufficiency/chronic
kidney disease
2 (14.2)20 (71.4)
Hyperlipidemia2 (71.4)14 (50)
Treatment
Hydroxychloroquine4 (57.1)25 (89.3)
Remdesivir‡1 (14.2)12 (42.9)
Days since onset of
symptoms§
27 (17–32)9 (1–16)9 (1–25)
Oxygen therapy/ARDS
Nasal cannula (oxygen < 6
liters)
3 (42.9)0
HFNC/NIV4 (4.3)
Ventilator non-ARDS2 (67.1)
Mild ARDS3 (10.7)
Moderate ARDS9 (32.1)
Severe ARDS10 (35.7)
ECMO1 (3.6)
Mortality0007 (25)

*Two severe COVID-19+ individuals were excluded from immunophenotyping and antibody quantification as they displayed clear outlier phenotype due to Rituxan treatment for lymphoma and acute lymphocytic leukemia, respectively.

†Underlying lung disease includes asthma, chronic obstructive pulmonary disease, and interstitial lung disease.

‡Donors enrolled in a clinical trial to test remdesivir versus placebo. Remdesivir was administered after blood collection.

§Days since onset of symptoms accounted from the time of blood collection.